Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complet...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2023-05, Vol.16 (1), p.58-58, Article 58
Main Authors: Nagler, Arnon, Labopin, Myriam, Blaise, Didier, Raiola, Anna Maria, Corral, Lucia Lopez, Bramanti, Stefania, Sica, Simona, Kwon, Mi, Koc, Yener, Pavlu, Jiri, Kulagin, Alexander, Busca, Alessandro, Rodríguez, Arancha Bermúdez, Reményi, Péter, Schmid, Christoph, Brissot, Eolia, Sanz, Jaime, Bazarbachi, Ali, Giebel, Sebastian, Ciceri, Fabio, Mohty, Mohamad
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Adult
Analysis
Blood & organ donations
Comorbidity
Cyclophosphamide
Cyclophosphamide - therapeutic use
Cytomegalovirus
De novo acute myeloid leukemia
Disease prevention
Graft versus host disease
Graft vs Host Disease - etiology
Graft-versus-host reaction
Haploidentical allogeneic stem cell transplantation
Hematology
Hematopoietic Stem Cell Transplantation - methods
Humans
Leukemia
Leukemia, Myeloid, Acute - complications
Medical prognosis
Middle Aged
Oncology
Patients
Post-transplantation cyclophosphamide
Recurrence
Remission
Remission (Medicine)
Retrospective Studies
Secondary acute myeloid leukemia
Stem cell transplantation
Stem cells
Transplantation
Transplantation Conditioning - methods
Transplantation outcomes
Transplantation, Haploidentical - methods
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8 years, p 
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-023-01450-4